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ABSTRACT
Background: Weight loss in obese individuals aims to reduce the
risk of type 2 diabetes by improving glycemic control. Yet, significant
intersubject variability is observed, and the outcomes remain poorly
predictable.
Objective: The aim of the study was to predict whether an individ-
ual will show improvements in insulin sensitivity above or below the
median population change at 6 mo after a low-calorie-diet (LCD) in-
tervention.
Design: With the use of plasma lipidomics and metabolomics for
433 subjects from the Diet, Obesity, and Genes (DiOGenes) Study,
we attempted to predict good or poor Matsuda index improvements
6 mo after an 8-wk LCD intervention (800 kcal/d). Three indepen-
dent analysis groups were defined: “training” (n = 119) for model
construction, “testing” (n = 162) for model comparison, and “vali-
dation” (n = 152) to validate the final model.
Results: Initial modeling with baseline clinical variables (body mass
index, Matsuda index, total lipid concentrations, sex, age) showed
limited performance [area under the curve (AUC) on the “testing
dataset” = 0.69; 95% CI: 0.61, 0.77]. Significantly better perfor-
mance was achieved with an omics model based on 27 variables
(AUC = 0.77; 95% CI: 0.70, 0.85; P = 0.0297). This model could
be greatly simplified while keeping the same performance. The sim-
plified model relied on baseline Matsuda index, proline, and phos-
phatidylcholine 0-34:1. It successfully replicated on the validation
set (AUC = 0.75; 95% CI: 0.67, 0.83) with the following charac-
teristics: specificity = 0.73, sensitivity = 0.68, negative predictive
value= 0.60, and positive predictive value= 0.80. Marginally lower
performance was obtained when replacing the Matsuda index with
homeostasis model assessment of insulin resistance (AUC = 0.72;
95% CI: 0.64, 0.80; P = 0.08).
Conclusions: Our study proposes a model to predict insulin sensi-
tivity improvements, 6 mo after LCD completion in a large popula-
tion of overweight or obese nondiabetic subjects. It relies on baseline
information from 3 variables, accessible from blood samples. This
model may help clinicians assessing the large variability in dietary
interventions and predict outcomes before an intervention. This trial
was registered at www.clinicaltrials.gov as NCT00390637. Am
J Clin Nutr 2018;108:13–23.
Keywords: obesity, insulin resistance, low-calorie diet, lipidomics,
metabolomics, plasma, predictive models
INTRODUCTION
Obesity is characterized by an excess of fat mass that af-
fects adipocyte metabolism and is associated with comorbidi-
ties such as cardiovascular diseases, insulin resistance, type 2 di-
abetes (T2D), and cancer (1). Numerous studies have reported
the causal link between obesity and T2D (2, 3). Dietary inter-
ventions aim to reduce fat mass, restore normal adipose tissue
(AT) function, and improve dysfunctions linked to metabolic syn-
drome (4). Yet, high variability is observed in the capacity to lose
and maintain weight (5). Within subjects who achieved weight
loss >8% of initial body weight, only half had glycemic con-
trol improvement (defined as improvements in insulin sensitivity)
(6). This stresses the need for clinical models to predict glycemic
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improvement. Although the literature is extensive with regard
to factors associated with the development of insulin resis-
tance and T2D (7, 8), it remains sparse with regard to pre-
dictors of glycemic outcomes after weight loss. We previously
proposed a model based on gene expression changes during
a low-calorie diet (LCD) (9). This model achieved very good
performance at predicting glycemic outcomes 6 mo after LCD
completion (AUC = 0.80; 95% CI: 0.69, 0.92). However,
this model may be difficult to implement in a routine clin-
ical setting, because it requires intrusive subcutaneous AT
biopsy samples taken at baseline and at LCD completion. Ide-
ally, biomarkers measured from blood samples would be pre-
ferred. Both metabolomics and lipidomics data can be ac-
quired from blood samples (plasma, serum) without the need
for intrusive biopsies and, as such, hold promise as predic-
tive markers. Several studies investigated the correlation be-
tween plasma metabolites and weight loss after bariatric surgery
(10, 11) or dietary intervention (12). Yet, these studies only re-
ported the association between individual metabolites and clini-
cal outcomes (weight loss, glycemic control improvements) and
did not construct predictive models. Therefore, it still remains un-
knownwhether these plasmamarkers would enable the prediction
of clinical outcomes with good performance.
In this report, we attempted to classify overweight or obese,
nondiabetic subjects from the Diet, Obesity, and Genes (DiO-
Genes) Study into good or lesser insulin sensitivity improvers
(as measured with the Matsuda index), 6 mo after an 8-wk LCD.
We tested ∼170 models with the use of methodologies ranging
from statistical tomachine learning, variables from 3 types of data
(clinical, plasma metabolomics, and lipidomics), and 3 different
time points (baseline, at LCD completion, and fold-changes dur-
ing LCD).
METHODS
Ethics
The study was performed according to the latest version of the
Declaration of Helsinki and was approved by local ethics com-
mittees with informed consent obtained by all of the participants.
Clinical study design
The DiOGenes study is a multicenter (8 European countries)
randomized, controlled, dietary intervention (clinicaltrials.gov;
NCT00390637). The study has been described previously
(13, 14) and a summary is shown in Figure 1A. Briefly, 938
overweight or obese nondiabetic adults underwent an 8-wk LCD.
The LCD provided 800 kcal/d with a meal-replacement prod-
uct (Modifast; Nutrition et Santé). During the LCD, 157 sub-
jects (17%) withdrew from the study. This drop-out rate was
extensively studied in Papadaki et al. (15). This rate is compara-
ble (even slightly lower) than in other weight-loss interventions
(16–19). In total, 781 subjects completed the LCD intervention,
with only 8who did not achieve 8%weight loss. The subjects who
achieved >8% weight loss (n = 773) were randomly assigned to
1 of 5 weight-maintenance diets (WMDs) for 26 wk. The diets
corresponded to a 2 × 2 factorial design: with high or low con-
tent in protein or glycemic index or a control diet according to
local food customs (20). Of those 773 participants, 548 (71%)
completed this 6-mo weight-maintenance intervention. This
drop-out rate (29%) has been previously discussed (5) and is in
line with reports from other studies (21, 22).
Improvement in insulin sensitivity was expressed as the per-
centage of increase of the Matsuda index between clinical in-
tervention day (CID) 1 (baseline) and CID3 (end of WMD).
The responder group was defined as subjects who show an
improvement in insulin sensitivity, as determined by an in-
crease in the Matsuda index greater than the population median
change [median = 40.36%, as defined by using the DiOGenes
completers with 75-g oral-glucose-tolerance test (OGTT) data;
n= 433]. The nonresponder class was composed of the remaining
individuals.
Subjects were classified as having impaired fasting glucose
if their fasting glucose concentrations were between 5.6 and
6.9 mmol/L as per American Diabetes Association recommen-
dations. Similarly, subjects were classified as having impaired
glucose tolerance if their 2-h OGTT glucose concentrations were
between 7.8 and 11 mmol/L.
Definition of analyses data sets
Among the 433 DiOGenes completers with available OGTT
data, 281 subjects had complete data (i.e., no missing values) for
both clinical and all plasma “omics” variables (see Figure 1B).
These subjects were used for discovery analyses. The remaining
subjects (n = 152) were kept for validation of final models. In
the discovery sample, statistical models were trained with sub-
jects from the DiOGenes leading centers (Denmark and Nether-
lands; n = 119). An independent testing set was built with the
individuals from the remaining 6 centers (n = 162) and was used
to identify the best-trained model.
Blood sampling
Blood samples were taken after an overnight fasting period at
baseline and upon completion of the LCD and WMD interven-
tions.
Clinical variables
The following clinical variables were included in the study:
age, sex, BMI, and fasting glucose and insulin concentrations.
The HOMA-IR was calculated as fasting glucose (mM)× fasting
insulin (μU/mL)/22.5. The Matsuda index, an established mea-
sure of insulin sensitivity (23), was derived from OGTTs with
measures at t = 0, 30, 60, 90, and 120 min. Total lipid concentra-
tions were measured from fasting blood samples and included
total triglycerides, total cholesterol, HDL cholesterol. LDL-
cholesterol concentrations were derived by using the Friedewald
formula.
Lipidomics and metabolomics analyses
Liquid chromatography–mass spectrometry data generation
was described previously (6). Metabolomics data generation (1H
nuclear magnetic resonance) was also described previously (24).
In total, 125 lipids and 18 metabolites were quantified (Supple-
mental Table 1).
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FIGURE 1 Study and analyses workflow. (A) DiOGenes dietary intervention; (B) analysis workflow and definition of the analysis data sets. The 2 leading
centers (Netherlands and Denmark) provided most of the food to participants during the weight-maintenance intervention (following recommendations from
dietitians and in accordance with the participant’s randomly assigned diet). This enabled a better monitoring of patients’ compliance during the WMD interven-
tion. The definition of glycemic responders was based on Matsuda index improvements ≥40.36%, as estimated for all DiOGenes completers (n = 433 subjects
with OGTT data). *The discovery data set was composed of subjects with complete data for all clinical variables (BMI,Matsuda index, total lipid concentrations
from blood biochemistry, age, sex, fasting glucose and insulin concentrations, HOMA-IR) and all omics variables (125 lipids from liquid chromatography–
mass spectrometry and 18 metabolites from nuclear magnetic resonance), and the validation data set was composed of subjects not included in the discovery
analyses and who had complete data for the Matsuda index and plasma concentrations of proline and PC O-34:1. CID, clinical intervention day; DiOGenes,
Diet, Obesity, and Genes; DK, Denmark; LCD, low-caloric diet; NL, Netherlands; OGTT, oral-glucose-tolerance test; PC O-31:1, phosphatidylcholine 0-34:1;
WMD, weight-maintenance diet.
Statistical analysis
Overall model strategy
A combination of different sets of variables (clinical variables
alone or in combinationwith omics data) was testedwith different
types of statistical models. This resulted in 169 different models
(13 data sets × 13 types of models).
Sets of predictors (data sets)
Thirteen different groups of variables (data sets) were tested
for model construction (Supplemental Table 1). The 13 data sets
used either the values at baseline, LCD termination, or the fold-
change during LCD.
Types of models
Thirteen different models from 4 distinct groups were tested,
as follows:
• Linear classification models: logistic regression, linear dis-
criminant analysis, and elastic nets
• Nonlinear models: neural network, support vector machine
(SVM), and k-nearest neighbors
• Tree-based models: random forest; and 3 boosting ap-
proaches: adaptive boosting algorithm (ADA), stochas-
tic gradient boosting [with Gradient Boosting Machine
(GBM)], and C5.0
• Bayesian approaches: Bayesian generalized linear model,
naive Bayes classifier, and Bayesian additive regression
trees
Model training and evaluation
Model training was performed with the caret framework (25).
Data preprocessing included variable standardization and re-
moval of variables with near-zero variance. Model training was
performed by using 10-fold cross-validation repeated 5 times.
Models were optimized over a grid of variables (Supplemental
Table 2). For ADA boosting, training was performed by using a
single 10-fold cross-validation. The superiority of a single model
was tested by using a 1-sided Delong’s test (26). Comparison be-
tween 2 families of a model was tested with a Wilcoxon’s Signed
Rank test. All of the analyses were performed with the R statis-
tical language (version 3.3.1; www.r-project.org), with all of the
statistical models being available through the caret framework
(25).
RESULTS
Overall clinical characteristics of the subjects
Clinical characteristics of the subjects are shown in Table 1.
At baseline, subjects had a mean ± SD age of 42 ± 6 y, with a
BMI (kg/m2) of 35 ± 5, a Matsuda index of 4.99 ± 2.82, and an
HOMA-IR of 3.05 ± 1.81.
After the LCD intervention, subjects had lost a mean ± SD
of −11.30 ± 3.36 kg. At study termination, these subjects had a
mean ± SD BMI of 31.36 ± 4.46, corresponding to a change of
−3.65 ± 2.39. The Matsuda index also improved with the LCD
(+2.22 ± 3.45) and the WMD (+1.57 ± 3.08) interventions.
Clinical characteristics of the 2 subject classes are also shown
in Table 1. As expected, upon classification into “responders”
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TABLE 1
Clinical characteristics of the subjects (discovery sample)1
Time point and variable All subjects (n = 281) Responders (n = 126) Nonresponders (n = 155) P
Baseline (CID1)
Age, y 42.18 ± 6.33 42.82 ± 6.37 41.66 ± 6.28 0.1299
Female sex, % 65 63 67 0.4529
BMI, kg/m2 34.98 ± 4.99 34.63 ± 4.54 35.27 ± 5.32 0.2788
Weight, kg 102.63 ± 18.18 103.05 ± 17.70 102.28 ± 18.61 0.722
Matsuda index 4.99 ± 2.83 3.83 ± 1.75 5.93 ± 3.18 2.26 × 10–11
HOMA-IR 3.05 ± 1.81 3.73 ± 2.05 2.48 ± 1.34 1.95 ×10–8
Fasting insulin, μU/mL 11.46 ± 6.49 13.84 ± 7.40 9.53 ± 4.87 6.15 × 10–8
Fasting glucose, mmol/L 5.07 ± 0.63 5.17 ± 0.61 4.98 ± 0.63 0.0115
Impaired fasting glucose, % 14.23 19.84 9.67 0.0168
Impaired glucose tolerance, % 24.73 30.64 20 0.0504
End of LCD (CID2)
BMI, kg/m2 31.14 ± 4.49 30.74 ± 4.10 31.46 ± 4.76 0.1699
Weight, kg 91.33 ± 16.21 91.44 ± 15.75 91.23 ± 16.61 0.915
Matsuda index 7.21 ± 3.66 7.39 ± 3.94 7.06 ± 3.41 0.4639
HOMA-IR 2.04 ± 1.92 1.91 ± 1.21 2.15 ± 2.34 0.255
Fasting insulin, μU/mL 8.03 ± 6.37 7.70 ± 4.78 8.31 ± 7.42 0.4017
Fasting glucose, mmol/L 4.83 ± 0.49 4.78 ± 0.50 4.86 ± 0.49 0.2089
Impaired fasting glucose, % 5.34 4.76 5.80 0.7935
Impaired glucose tolerance, % 27.47 33.05 23.02 0.0763
End of WMD (CID3)
BMI, kg/m2 31.36 ± 4.46 30.72 ± 4.09 31.87 ± 4.69 0.0298
Weight, kg 91.99 ± 16.47 91.35 ± 15.96 92.50 ± 16.91 0.5615
Matsuda index 6.56 ± 3.36 7.74 ± 3.55 5.61 ± 2.87 1.21 × 10–7
HOMA-IR 2.47 ± 2.29 1.89 ± 1.22 2.94 ± 2.80 4.16 × 10–5
Fasting insulin, μU/mL 9.50 ± 8.42 7.57 ± 5.45 11.07 ± 9.97 0.0002
Fasting glucose, mmol/L 4.99 ± 0.51 4.88 ± 0.45 5.07 ± 0.55 0.0012
Impaired fasting glucose, % 8.89 5.55 11.61 0.0927
Impaired glucose tolerance, % 10.10 9.60 10.52 0.8436
Changes during LCD
Change in BMI, kg/m2 −3.85 ± 1.06 −3.90 ± 1.01 −3.81 ± 1.10 0.4787
Change in BMI, % −10.98 ± 2.47 −11.24 ± 2.49 −10.78 ± 2.43 0.1194
Change in fasting glucose, mmol/L −0.24 ± 0.53 −0.39 ± 0.46 −0.12 ± 0.56 1.92 × 10–5
Change in fasting glucose, % −3.77 ± 13.67 −7.02 ± 8.26 −1.14 ± 16.40 1.28 × 10–4
Change in HOMA-IR −1.00 ± 2.04 −1.82 ± 1.79 −0.32 ± 1.98 1.47 × 10–10
Change in HOMA-IR, % −24.79 ± 52.19 −42.92 ± 31.64 −9.87 ± 60.52 1.58 × 10–8
Change in fasting insulin, μU/mL −3.43 ± 6.64 −6.14 ± 6.18 −1.22 ± 6.18 1.74 × 10–10
Change in fasting insulin, % −22.59 ± 48.74 −38.90 ± 31.05 −9.33 ± 56.06 5.80 × 10–8
Change in Matsuda index 2.22 ± 3.45 3.56 ± 3.49 1.13 ± 3.01 2.96 × 10–9
Change in Matsuda index, % 67.65 ± 111.25 113.23 ± 142.76 30.61 ± 53.65 6.33 × 10–9
Change in weight, kg −11.30 ± 3.36 −11.61 ± 3.38 −11.05 ± 3.33 0.1605
Change in weight, % −10.98 ± 2.47 −11.24 ± 2.49 −10.78 ± 2.43 0.1194
Changes during WMD
Change in BMI, kg/m2 −3.65 ± 2.39 −3.96 ± 2.24 −3.40 ± 2.47 0.0486
Change in BMI, % −10.20 ± 6.01 −11.23 ± 5.79 −9.38 ± 6.08 0.0101
Change in fasting glucose, mmol/L −0.08 ± 0.58 −0.29 ± 0.50 0.09 ± 0.58 7.97 × 10–9
Change in fasting glucose, % −0.51 ± 14.02 −5.00 ± 8.84 3.14 ± 16.25 2.09 × 10–7
Change in HOMA-IR −0.57 ± 2.36 −1.83 ± 1.54 0.47 ± 2.41 4.32 × 10–19
Change in HOMA-IR, % −6.90 ± 85.07 −46.90 ± 18.20 26.05 ± 102.69 5.38 × 10–15
Change in fasting insulin, μU/mL −1.96 ± 7.98 −6.27 ± 5.13 1.54 ± 8.18 2.08 × 10–19
Change in fasting insulin, % −8.04 ± 68.07 −44.09 ± 17.94 21.26 ± 78.97 7.63 × 10–19
Change in Matsuda index 1.57 ± 3.08 3.91 ± 2.42 −0.33 ± 2.10 2.73 × 10–38
Change in Matsuda index, % 49.64 ± 75.70 111.28 ± 70.35 −0.47 ± 27.68 7.26 × 10–37
Change in weight, kg −10.66 ± 6.97 −11.75 ± 6.73 −9.78 ± 7.05 0.0181
Change in weight, % −10.20 ± 6.01 −11.23 ± 5.79 −9.38 ± 6.08 0.0101
1Values are means± SDs unless otherwise indicated. Descriptive statistics are shown for the 281 subjects used in the discovery analyses, including the 126
responders and the 155 nonresponders. Clinical characteristics of these subjects are representative of the whole DiOGenes cohort. CID1= baseline, CID2= end
of LCD intervention, and CID3 = end of WMD intervention. P values compare responders and nonresponders. For numerical variables, a 2-sided t test was
used; for categorical variables (e.g., impaired glucose tolerance, impaired fasting glucose, sex), a Fisher’s exact test was used. CID, clinical intervention day;
DiOGenes, Diet, Obesity, and Genes; LCD, low-calorie diet; WMD, weight-maintenance diet.
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and “nonresponders,” some differences can be observed. Notably,
these groups differed in baseline Matsuda index (P = 2.26 ×
10−11). This observation was consistent with the use of fasting
glucose and insulin concentrations as well as HOMA-IR. Sig-
nificant differences were also found in the proportion of sub-
jects with impaired fasting glucose (see definition in Methods)
between responders and nonresponders (19.84% compared with
9.67%; P = 0.0168). There was a tendency for a difference in the
proportion of subjects with impaired glucose tolerance (30.64%
compared with 20%; P = 0.0504). This is in line with the above-
mentioned observations using continuous measures of insulin
sensitivity.
An investigation of other factors (age and sex) did not show
significant differences between responders and nonresponders
(P > 0.05). Finally, the 2 groups had similar baseline BMI (P =
0.28) and had no significant difference in the percentage ofweight
loss (P = 0.12) but displayed significant difference in weight
maintenance (P = 0.018).
The strong differences at baseline in indexes of insulin sen-
sitivity between responders and nonresponders suggested some
potential to predict glycemic outcomes. Indeed, the baseline
Matsuda index and the percentage of Matsuda changes be-
tween CID1 and CID3 were significantly correlated (Pearson’s
r = −0.42; 95% CI: −0.51, −0.32; Supplemental Figure 1).
However, this correlation was not perfect, indicating that addi-
tional factors could affect the final glycemic outcome. In ad-
dition, although the proportion of subjects who could be con-
sidered insulin-resistant (baseline Matsuda index ≤2.5) was
significantly higher in the responder group than in the nonre-
sponder group (37.6% compared with 12.5%; Fisher’s exact test,
P = 1.3 × 10–9), this was not sufficient for prediction pur-
poses. Indeed, a stratification model based on baseline insulin
resistance status, sex, and age yielded a classification perfor-
mance comparable to a random prediction (AUC on the testing
set = 0.59; 95% CI: 0.49, 0.68). The use of other thresholds
(Matsuda index ≤3) or other variables (HOMA-IR) led to sim-
ilar performance. The addition of baseline BMI in these models
also led to similar performance. This suggests that additional fac-
tors would need to be included in the model to achieve a better
prediction.
Initial modeling of insulin sensitivity improvements
On the basis of the observations from Table 1, we attempted
a simple model based on baseline clinical variables (BMI, Mat-
suda index, sex, age, and total lipid concentrations from biochem-
istry). Following best practices from the field, the data were split
into a training set (n = 119, for model construction) and a testing
set (n = 162, for evaluating performance). The 2 data sets were
comparable: subjects had similar weight and insulin sensitivity
during the LCD and after weight maintenance. We then used a lo-
gistic regression to classify responders and nonresponders. This
preliminary model provided modest performance (AUC on test-
ing set= 0.69; 95% CI: 0.61, 0.77). The same model substituting
the Matsuda index with HOMA-IR led to a slightly lower per-
formance (AUC = 0.66; 95% CI: 0.57, 0.74). The replacement
of the HOMA-IR with fasting glucose and insulin concentrations
resulted in the same performance.
Performance of 169 modeling approaches
To identify models with potentially better performance, we ex-
plored the combination from 13 different sets of predictors and
13 different modeling approaches, ranging from simple statis-
tical approaches to more complex, machine-learning methods.
Figure 2A summarizes the performance from all models. Ap-
proximately half of the models (89 of 169) were not better than
a random predictor (with AUCs not significantly different from
0.50). In contrast, some models showed very good performance,
with AUCs >0.75 and 95% CIs strictly greater than 0.50.
We investigated whether data from a specific time point (base-
line, at LCD termination, or fold-change during LCD) would of-
fer a better classification performance. Figure 2B shows the per-
formance grouped by data set time point. Models based on data
collected at LCD completion (CID2) had significantly lower per-
formance thanmodels built with baseline values (at CID1) or with
fold-changes (Wilcoxon’s Signed Rank test, P < 5%). Approx-
imately 70% of the models based on CID1 data had a perfor-
mance better than a random classifier. This proportion was∼80%
for data sets based on fold-changes, and it dropped to only 11%
for data sets based on CID2 variables. Therefore, prediction of
glycemic outcomes is best achieved by using either baseline in-
formation or the trajectories during weight loss.
Next, we searched whether specific statistical framework
would lead to better performance than others. Figure 2C presents
the performance grouped by type of model. It shows that elas-
tic net models generally perform best (median AUC = 0.70;
IQR = 0.16). The second best class of model pertains to boost-
ing algorithms represented with the stochastic gradient boosting
(GBM boosting; median AUC = 0.65; IQR = 0.15) and ADA
boosting (median AUC = 0.64; IQR = 0.14). Elastic nets out-
performed those 2 types of models (P < 0.006). Logistic re-
gressions showed large variability in their performance and were
outperformed by elastic nets (P = 0.0017), reflecting their lim-
itations in the presence of numerous variables. Specific models,
such as k-nearest neighbors, SVM, Naïve Bayes, and C5.0 boost-
ing methods, had poor performance, likely due to their need for
very large training data sets, which is not achievable in clinical
studies.
Description of the top omics model
Our best omics model showed the following classification per-
formance: AUC = 0.77 (95% CI: 0.70, 0.85). This model, based
on an elastic net and baseline variables, retained 27 predictors
with a non-zero coefficient (Supplemental Table 3); other vari-
ables were not considered informative by the model. The overall
performance of the omics model is shown in Figure 3A. It out-
performed the clinical model (Delong’s P = 0.0297) and strong
differences were observed. For example, by using a specificity
cutoff at 80%, the omics model reached 65% sensitivity whereas
the clinical model only reached 37%. By defining the optimal re-
ceiver operating characteristic (ROC) threshold with the use of
the Youden index, the omics model obtained the following per-
formance: 87% specificity, 61% sensitivity, and 77% and 75%
negative and positive predictive values (NPVs and PPVs), re-
spectively. By contrast, the clinical model only obtained 45%
specificity, 86% sensitivity, and 83% and 51% NPVs and PPVs,
respectively.
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FIGURE 2 Performance of the 169 models. (A) Histogram of all 169 values of ROCAUCs. The dotted blue line indicates an AUC= 0.50, the performance
of a random classifier. (B) Performances grouped by the time point of the variables involved in the models. (C) Performances grouped by the statistical approach
used to construct the classification models. ADA, adaptive boosting algorithm; BART, Bayesian additive regression trees; CID, clinical intervention day; GBM,
Gradiant Boosting Machine; GLM, generalized linear model; LCD, low-calorie diet; ROC, receiver operating characteristic; SVM, Support Vector Machine.
Next, we analyzed the importance of the variables in the omics
model (Figure 3B). The Matsuda index was found to be the most
informative variable for the prediction of its own evolution after
weight maintenance, as expected. Several omics variables were
selected by the elastic net and improved the model performance.
The second most important variable, phosphatidylcholine (PC O-
34:1) had a relative importance>60% (this variable was as infor-
mative as 60% of the information carried by the Matsuda index).
Proline, the third most important variable, had a relative impor-
tance>50%. BMIwas incorporated in themodel, but only ranked
as number 15. The model did not select sex and age, suggesting
that these variables did not add significant information.
Effect of WMDs
We tested whether considering the WMD would improve the
prediction. We modeled the WMD with the use of 3 different
approaches. We first represented the diet as a categorical vari-
able (representing each of the 5 possible diets). Second, we
expressed the diet into 2 categorical variables, one representing
the protein content (high or low) and the other corresponding
to the glycemic index (high or low). Finally, we used quantita-
tive information about protein and carbohydrate macronutrient
intakes, as derived from 3-d food diaries (collected within the first
2–4wk of theWMDphase). In all approaches, the performance of
previous models was not significantly improved (P > 0.36), sug-
gesting that diet had little influence on the prediction of insulin
sensitivity improvements when compared with the information
already included in the omics model.
Testing additional model optimization
We tested whether adding the percentage of weight loss dur-
ing the LCD intervention would help refine the performance
of our omics model. However, the resulting AUC was identi-
cal: 0.76 (95% CI: 0.68, 0.83). Similarly, a model that used the
percentage of Matsuda index improvement during the LCD did
not improve the performance (AUC = 0.75; 95% CI: 0.67,
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FIGURE 3 Performance of classification models. (A) ROC curves showing classification performance as obtained on the testing data set. The omics
model outperforms the clinical model (Delong’s P = 0.0297). The diagonal line indicates the performance from a random predictor. (B) Plot of relative
variable importance from the top elastic net. Importance is relative to the top predictor (the one with the highest absolute coefficient). (C, D) ROC curves
showing the performance on the testing set and validation set for the simplified omics models with the use of either the Matsuda index (C) or HOMA-IR (D),
together with baseline proline and PC O-34:1 concentrations. CID, clinical intervention day; PC, phosphatidylcholine; PE, phosphatidylethanolamine; ROC,
receiver operating characteristic; SM, sphygingomyelin; TG, triglyceride.
0.82). Models that used additional anthropometric variables did
not yield better performance: adding waist circumference, hip
circumference, or body fat mass all led to AUCs close to
0.63. Adding the waist-to-hip ratio resulted in poor performance
(AUC = 0.58; 95% CI: 0.49, 0.68).
We also tested whether the Matsuda index could be replaced
in our models by HOMA-IR. The resulting performance was
slightly lower (AUC = 0.74; 95% CI: 0.67, 0.82), but this dif-
ference was not significant (P = 0.27). A model with glucose
and insulin fasting variables instead of HOMA-IR led to a simi-
lar performance (0.73; 95% CI: 0.66, 0.81). This suggested that,
in the absence of OGTT data, HOMA-IR or fasting concentra-
tions could be a suitable replacement with minimal loss of the
model performance.
Replacing the Matsuda index with either the impaired
glucose tolerance status or impaired fasting glucose status
yielded significantly lesser performance (P = 1.4 × 10–4),
with AUCs close to 0.66 (and 95% CIs ranging from ∼0.58
to 0.75). This is expected because a model based on a
continuous predictor would perform and be more robust
than a model that uses a discretized version of this same
variable (27).
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Model simplification
In an attempt to simplify our model (27 variables), we con-
structed a new model based only on the top 3 variables (Matsuda
index, proline, and PC O-34:1 at baseline). In the testing data set,
this simplified model reached a performance (AUC = 0.77; 95%
CI: 0.70, 0.85) similar to the full model (P = 0.43).
We further challenged the performance with the use of 152
subjects who had not been included in any previous analyses (see
Figure 1B; clinical characteristics of this validation data set are
shown in Supplemental Table 4 and are representative of both
the whole DiOGenes cohort and of the discovery data set). In this
additional validation data set, the performance was confirmed,
with an AUC= 0.75 (95% CI: 0.67, 0.83) (see Figure 3C), which
shows the robustness of the model. Model coefficients and de-
scriptive statistics for each variable are available in Supplemen-
tal Tables 5 and 6.
We also tested a simplified model based on the HOMA-IR
instead of the Matsuda index. Here, performances were good:
AUC = 0.77 (95% CI: 0.69, 0.84) in the testing set and a
slightly lower AUC (0.72; 95% CI: 0.64, 0.80) in the valida-
tion set (Figure 3D). Compared with the Matsuda index–based
model, this HOMA-IR model had marginally lower performance
(P = 0.08).
Finally, we compared the performance in terms of sensitivity
and specificity, as well as PPV and NPV (Supplemental Table
7). These metrics were derived from the ROC curve on the vali-
dation data set, and the best ROC threshold was obtained by us-
ing the Youden index. Both models provided similar and good
specificity of >73% and a PPV >77%. However, the model that
used the Matsuda index was more sensitive than the HOMA-IR–
basedmodel (sensitivity= 68.48% comparedwith 57.61%). Sim-
ilar observations were made with the NPV (60.27% compared
with 54.12%). The use of a different approach to find the optimal
ROC threshold (specificity set at 80%) led to the same conclu-
sions (Supplemental Table 7).
These simplified models can be interpreted as follows: non-
responders include more subjects with good insulin sensi-
tivity at baseline (high Matsuda index or low HOMA-IR;
Figure 4A, B). Nonresponders also tend to have lower plasma
PC O-34:1 concentrations and higher proline concentrations than
responders (Figure 4C, D). Each of the individual variables shows
some variability and overlap between responders and nonrespon-
ders. This shows that prediction cannot easily be achieved by us-
ing only 1 variable (as expected). Instead, the combination of 3
variables is required and leads to very good performance. This is
expected because if a single variable had shown a clear separation
between the groups, then our multivariate approach (combined
with its intrinsic regularization and feature selection) would have
kept only this variable in the final model.
DISCUSSION
This study explored approaches to predict glycemic outcomes
6 mo after an LCD in obese, nondiabetic subjects. We found
significant differences in baseline glycemic control between re-
sponders and nonresponders. Specifically, subjects with better
baseline insulin sensitivity had less room for improvement af-
ter the dietary intervention. However, a model based on baseline
insulin-resistant status offered poor performance (AUC = 0.59;
95%CI: 0.48, 0.67). Prediction was improved by combiningmul-
tiple variables (baseline BMI, Matsuda index, total lipid con-
centrations, sex, and age). This clinical model achieved better,
yet modest, performance with an AUC = 0.69 (95% CI: 0.61,
0.77). Incorporating plasma metabolites and lipids enabled the
model to significantly improve its performance (AUC = 0.77;
95% CI: 0.70, 0.85). This omics model corresponded to improve-
ment in both sensitivity and specificity and outperformed the clin-
ical model (P = 0.0297). Additional variables, such as the WMD
arm, BMI, or glycemic changes during the LCD, did not im-
prove the performance. This final performance was comparable
to the one from our recent model based on transcriptomics anal-
yses from AT biopsy sample (9), which reached an AUC = 0.80
(95% CI: 0.69, 0.92). Importantly, our new omics model, based
on circulating markers, provides better translational potential be-
cause it does not depend on intrusive procedure (AT biopsy sam-
ples both at baseline and at LCD termination), while keeping a
comparable performance. However, this omics model depends on
27 variables, which might challenge its application in a clinical
context. Subsequent analyses greatly simplified this model. In
particular, the use of only the 3 top variables (baseline Matsuda
index and proline and PC O-34:1 concentrations) provided iden-
tical performance than the full omics model. This performance
was confirmed on a second validation sample (n = 152), with
an AUC = 0.75 (95% CI: 0.67, 0.83). Additional metrics reflect-
ing the quality of our predictions can be found in Supplemen-
tal Table 7 (e.g., the simplified model has >73% specificity and
>79% PPV).
This simplified model offers better translational potential than
the full omics model, because it relies only on the Matsuda index
and proline and PC O-34:1 concentrations. The Matsuda index
can be measured from an OGTT. We found that, in the absence
of such data, the HOMA-IR would represent a good compromise
(with a model presenting an AUC = 0.72; 95% CI: 0.64, 0.80).
Amino acid concentrations are already tested in clinical prac-
tice (28) [e.g., for the diagnosis of inborn error of metabolism
in newborns (29)]. Lipids are becoming increasingly important
for the prediction of clinical outcomes [e.g., for the prediction
of cardiovascular events in subjects with T2D (30)]. Current ad-
vances in the field make this class of molecule easier to be ac-
quired in a clinical context (e.g., using targeted approaches) (31,
32). Although not all clinics may have access to in-house omics
facilities, both proline and PC O-34:1 markers are available on
standard panels from external companies. Those commercial as-
says can be run on standard liquid chromatography–mass spec-
trometry machines (frequently available in universities or in large
obesity clinics with translational research activities). The analy-
sis can also be fully outsourced to the same commercial com-
panies that provide these panels and to numerous other service
companies.
The presence of proline and phosphatidylcholine in our model
is not completely surprising, although they were not previ-
ously known as predictors of glycemic improvements (e.g.,
improvements in insulin sensitivity index). Proline plasma con-
centrations are known to be associated with obesity and insulin-
resistance markers (BMI, HOMA-IR, and glycated hemoglobin,
C-peptide, insulin, and leptin concentrations); specifically, higher
proline concentrations are observed in hyperinsulinemic patients
(33). Phosphatidylcholines are major components of the cellu-
lar membranes and play an important role in regulating lipid,
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FIGURE 4 Boxplots of baseline values for the top (most predictive) variables from the simplified models, stratified by responders and nonresponders, for
baseline Matsuda index (A), HOMA-IR (B), and concentrations of PC O-34:1 (C) and proline (D). PC, phosphatidylcholine.
lipoprotein, and whole-body energy metabolism (34). The
content and alteration of PUFA-containing phospholipids in
muscle are associated with insulin resistance (35). A recent
metabolomics study (36) has shown the interplay between phos-
phatidylcholines, iron homeostasis, and glucose metabolism.
Another study (37) found that changes in phosphatidylcholine
concentrations after Roux-en-Y gastric bypass were associated
with insulin sensitivity (HOMA-S), and that these changes were
independent of weight loss. This is consistent with our results and
the characteristics of the 2 patient groups (Figure 4)
Interestingly, branched-chain amino acids (BCAAs;
isoleucine, valine, leucine) were not retained in our models. This
suggests that, although BCAAs are prognostic markers of insulin
resistance (7), these variables are not considered informative
for the prediction of glycemic outcomes. This is consistent
with a recent analysis of the Preventing Overweight Using Novel
Dietary Strategies Trial (POUNDS LOST) (n= 774) and Dietary
Intervention Randomized Controlled Trial (DIRECT) (n = 318)
studies, which that did not identify any significant association
between change in BCAA concentrations and HOMA-IR im-
provements (12). Finally, adiposity (BMI and other measures
such as waist circumference and body fat mass) had limited
importance in our models. In the full omics model, baseline BMI
only ranked as the 15th (out of 27) most-informative variable.
Incorporating weight-loss trajectories during the LCD did not
significantly improve the performance. Therefore, weight-related
variables provide very limited information in predictive models
because they fail to capture the metabolic state of the individual
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(as opposed to the information carried by metabolites and lipids).
This finding is in agreement with our recent lipidomics study (6)
and stresses further the importance of lipid metabolism for the
prediction of glycemic control improvements. The independence
of the model with respect to weight-related variables also raises
the question of whether it might be applicable to the prediction
of glycemic improvements upon slight caloric-restriction or
lifestyle intervention in a population of nonobese subjects. This
would need to be formally tested in large cohorts such as the
Look Ahead (38) or Diabetes Prevention Program (39). Our
model may also be useful in cohorts of patients with more severe
insulin resistance (e.g., cohorts of morbidly obese patients),
to better study the variability in glycemic outcomes after an
intervention (either LCD or surgery). This would also require
formal testing and would likely require access to better tools
(e.g., euglycemic clamp) to assess the degree of insulin resistance
in such patients.
Finally, the recent study by Lean et al. (40) showed the supe-
rior efficacy of LCD studies over the current primary care prac-
tices (best practices by guidelines) in the management of obese
subjects with T2D. Their LCD intervention yielded significant
differences in terms of weight loss (with 24% of participants
from the LCD group and 0% in the primary care group having
>15 kg of weight loss at 1 y). Significant differences were also
seen for the percentages of T2D remission (46% compared with
4% in the LCD and primary care groups, respectively). One
would expect that LCD interventions will become increasingly
important and present in the management of obese or prediabetic
patients or those with T2D. Because the products used in LCDs
provide similar daily caloric intake (800–900 kcal/d), our present
results should apply to any such LCD study. In our study, we
observed a drop-out rate of ∼17% during the LCD and we, de
facto, could not include those subjects in our analyses due to lack
of data. However, this number is in line with other multicenter
weight-loss studies (16–19), and it does not challenge the gen-
eralization of our findings to other LCD studies that would face
similar drop-out rates.
In conclusion, our study identified a model that enables the
prediction of improvements in insulin sensitivity in a large popu-
lation of overweight or obese subjects. This model relies on base-
line information from only 3 variables that are accessible from
blood samples. In addition, the performance is comparable to a
more intrusive model that relies on molecular phenotyping from
AT biopsy samples at 2 time points (baseline and after an LCD).
To the best of our knowledge, there is no established model to
predict glycemic outcomes; therefore, the proposed model de-
fines a first standard that could serve as a benchmark for future
models. This model already provides some potential for clinical
practice and may help clinicians in understanding the large vari-
ability in dietary interventions. Finally, our modeling strategies
might guide other biomarker studies that aim to predict clinical
outcomes after an intervention.
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